思力华能倍乐多少钱一盒

When it comes to chronic obstructive pulmonary disease (COPD), friends in the respiratory department must be familiar with it. The disease is characterized by shortness of breath (difficulty breathing), cough, wheezing, and expectoration (mucoid or purulent). For patients, COPD is no longer just a "breathing pain". In my country alone, the number of people dying from COPD every year is as high as 1.28 million. According to the World Health Organization, COPD will become the third leading cause of death and the fifth leading cause of disability in the world by 2030. The emergence of has greatly alleviated this situation.

The editor would like to remind everyone that due to the different exchange rates at home and abroad, please consult Medical Travel for the specific price of Sliva Respimat. And on June 3, 2014, the German pharmaceutical giant Boehringer Ingelheim (BI) announced that its new soft mist inhalation device-Silivar (tiotropium bromide) Respimat was officially launched in China. The device uses innovative design and technology to make up for various shortcomings of existing inhalers, achieving easy inhalation, efficient lung deposition, and easy operation and portability. It will bring a more efficient, safe and convenient new treatment option to the majority of patients with COPD.

The first prototype of the device was launched in 1991 and consisted of nearly 100 individual components. After continuous iterative development, the new generation of Respimat launched this time requires only 28 components and can produce 230 million independent droplets with one press. The active ingredients of the drug are fully atomized. Therefore, compared with other inhalation devices, the internal design of the device allows the spray to be completely generated by the mechanical device without propellant. The patient has longer time to inhale the drug and allow it to reach the lungs.

The 2014 version of the GOLD Guidelines, regarded as the "bible" by respiratory doctors, continues to emphasize that long-acting anticholinergic drugs represented by tiotropium bromide are still the main recommended drugs for the treatment of COPD. At the same time, it is specifically mentioned in the update section that the old view that the use of soft mist inhalers to administer Slivar Respimat or increase the risk of patient death has been eliminated by new large-scale RCTs. The trial refutes this, that is, there is no difference in patient mortality and risk of acute exacerbation between tiotropium bromide inhaled through dry powder inhalation and soft mist inhaler.

Recommended related hot articles: /newsDetail/82290.html